Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors

US12064421B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Harald Engelhardt · Ebreichsdorf, AT
• Mark PETRONCZKI · Wien, AT
• Juergen Ramharter · Wien, AT
• Ulrich Reiser · Wien, AT
• Heinz Stadtmueller · Wien, AT
• Dirk Scharn · Wien, AT
• Tobias Wunberg · Mödling, AT

Key dates

• Filing date: Oct 29, 2021
• Grant date: Aug 20, 2024
• Expiry date: Sep 29, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/541
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention encompasses compounds of formula (I) wherein the groups R1 to R4 and X1 to X5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.